Allergy Therapeutics (LSE:AGY) Total Liabilities: £66.76 Mil (As of Dec. 2025)


What is Allergy Therapeutics Total Liabilities?

Allergy Therapeutics LSE:AGY +1.52% Total Liabilities is £66.76 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Allergy Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was £66.76 Mil.

Allergy Therapeutics's quarterly Total Liabilities increased from Dec. 2024 (£80.12 Mil) to Jun. 2025 (£95.74 Mil) but then declined from Jun. 2025 (£95.74 Mil) to Dec. 2025 (£66.76 Mil).

Allergy Therapeutics's annual Total Liabilities declined from Jun. 2023 (£64.32 Mil) to Jun. 2024 (£59.05 Mil) but then increased from Jun. 2024 (£59.05 Mil) to Jun. 2025 (£95.74 Mil).

Allergy Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics Total Liabilities Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.55 35.18 64.32 59.05 95.74

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.62 59.05 80.12 95.74 66.76

Allergy Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Allergy Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=27.192+(58.209+1.743
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+8.592+0)
=95.74

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=67.543--28.193
=95.74

Allergy Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=32.029+(24.787+1.705
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+8.234+0)
=66.76

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=71.004-4.249
=66.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of £66.76 Mil mean?
Allergy Therapeutics (LSE:AGY) has a Total Liabilities of £66.76 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Allergy Therapeutics and its competitors.
Is Allergy Therapeutics' Total Liabilities too high?
Allergy Therapeutics' current Total Liabilities is £66.76 Mil.
How does Allergy Therapeutics' Total Liabilities compare to ZTS and UTHR?
Allergy Therapeutics' Total Liabilities of £66.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Allergy Therapeutics and its competitors. Allergy Therapeutics's current Total Liabilities is £66.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 123.3% above its estimated fair value. The current Total Liabilities is £66.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Total Liabilities is £66.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).